STOCK TITAN

Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Orchestra BioMed (Nasdaq: OBIO) will participate in the Piper Sandler 38th Annual Healthcare Conference in New York City on December 1–3, 2026.

Chairman and CEO David Hochman will join a fireside chat hosted by Piper Sandler analyst Matthew O’Brien on December 2 at 9:00 a.m. ET. Management will also hold one-on-one investor meetings. A live webcast will be accessible through the company’s Investor Relations website, with a replay available afterward.

Loading...
Loading translation...

Key Terms

pharmacokinetics, breakthrough device designation, in-stent restenosis
3 terms
pharmacokinetics medical
"exceeded the published pharmacokinetics of leading limus drug-eluting stents"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
breakthrough device designation regulatory
"AVIM Therapy has two FDA Breakthrough Device Designations."
A breakthrough device designation is a regulatory program that gives promising medical devices for serious or life‑threatening conditions priority support and faster review from a health authority (e.g., the U.S. FDA). Think of it as a “fast lane” or VIP pass through development and review: it can shorten time to market, lower regulatory uncertainty, and boost a company’s commercial prospects — but it is not an approval by itself.
in-stent restenosis medical
"positive three-year clinical data in coronary In-Stent Restenosis in the SABRE study"
In-stent restenosis is the re-narrowing of an artery at the site where a metal or drug-coated tube (stent) was placed to keep it open, caused by scar tissue or cell growth inside the stent. For investors, it matters because it drives demand for follow-up treatments, influences the perceived effectiveness and safety of stent products, and can affect regulatory scrutiny, reimbursement and long-term sales for companies that make stents or therapies to prevent or treat re-narrowing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NEW HOPE, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, today announced that management will participate in the Piper Sandler 38th Annual Healthcare Conference being held December 1-3, 2026, in New York City. David Hochman, Chairman and Chief Executive Officer, will participate in a fireside chat hosted by Matthew O’Brien, Managing Director, Senior Research Analyst at Piper Sandler on Wednesday, Dec. 2, 2026, at 9:00am ET. Management will also host one-on-one meetings with investors during the event.

A live webcast of the event will be accessible through Orchestra BioMed’s Investor Relations website and will be available for replay following the event.

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates, Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB), are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities.

AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic (NYSE: MDT), one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has two FDA Breakthrough Device Designations. The BACKBEAT Trial evaluating AVIM Therapy has completed enrollment.

Virtue SAB is a first-of-its-kind, non-coated drug delivery AngioInfusion™ balloon system designed to infuse a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB exceeded the published pharmacokinetics of leading limus drug-eluting stents and demonstrated positive three-year clinical data in coronary In-Stent Restenosis in the SABRE study, a multi-center prospective, independent core lab-adjudicated pilot clinical study of 50 patients conducted in Europe. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease, in each case, within specified parameters. The Virtue Trial evaluating Virtue SAB for the treatment of coronary in-stent restenosis is currently enrolling patients.

CAUTION: Investigational devices. Limited by United States law to investigational use.

For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

Investor Contact:
Silas Newcomb
Orchestra BioMed
snewcomb@orchestrabiomed.com

Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com


Keep reading